The global market for Melanoma Skin Cancer Diagnostic Testing was estimated to be worth US$ 715 million in 2023 and is forecast to a readjusted size of US$ 1210.4 million by 2030 with a CAGR of 7.9% during the forecast period 2024-2030

Melanoma Skin Cancer Diagnostic Testing - Market

Melanoma skin cancer is the most dangerous type of skin cancer. Development of defective DNA due to exposure to the ultraviolet radiation from sunlight or tanning beds leads to develop melanoma skin cancer. This genetic defect triggers mutation in the cell structure resulting in rapid multiplication of cells forming a malignant tumor. These malignant tumors often originate at basal layer of epidermis which produces melanocyte type of pigment which makes most of melanoma skin cancer black or brown in color. As per skin cancer foundation, in 2018 around 178,560 cases of melanoma will be diagnosed in United States alone. Melanoma skin cancer is the least common type of skin cancer and it is curable if diagnosed early. Early melanoma skin cancer diagnostic testing plays major role future treatment regimen and possible cure for the patient.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Melanoma Skin Cancer Diagnostic Testing, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Melanoma Skin Cancer Diagnostic Testing by region & country, by Type, and by Application.

The Melanoma Skin Cancer Diagnostic Testing market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Melanoma Skin Cancer Diagnostic Testing.

Market Segmentation

Scope of Melanoma Skin Cancer Diagnostic Testing - Market Report

Report Metric	Details
Report Name	Melanoma Skin Cancer Diagnostic Testing - Market
Forecasted market size in 2030	US$ 1210.4 million
CAGR	7.9%
Forecasted years	2024 - 2030
Segment by Type:	Biopsy Imaging Others
Segment by Application	Hospitals Dermatology Clinics Diagnostic Laboratories Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Myriad Genetics, Abbott Laboratories, Foundation Medicine, Pathway Genomics Corporation, Cancer Genetics, Castle Biosciences, NeoGenomics, Dermtech, Sysmex Inostics
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Melanoma Skin Cancer Diagnostic Testing manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Melanoma Skin Cancer Diagnostic Testing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Melanoma Skin Cancer Diagnostic Testing in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the Melanoma Skin Cancer Diagnostic Testing - Market size in 2030?

Ans: The Melanoma Skin Cancer Diagnostic Testing - Market size in 2030 will be US$ 1210.4 million.

Who are the main players in the Melanoma Skin Cancer Diagnostic Testing - Market report?

Ans: The main players in the Melanoma Skin Cancer Diagnostic Testing - Market are Myriad Genetics, Abbott Laboratories, Foundation Medicine, Pathway Genomics Corporation, Cancer Genetics, Castle Biosciences, NeoGenomics, Dermtech, Sysmex Inostics

What are the Application segmentation covered in the Melanoma Skin Cancer Diagnostic Testing - Market report?

Ans: The Applications covered in the Melanoma Skin Cancer Diagnostic Testing - Market report are Hospitals, Dermatology Clinics, Diagnostic Laboratories, Others

What are the Type segmentation covered in the Melanoma Skin Cancer Diagnostic Testing - Market report?

Ans: The Types covered in the Melanoma Skin Cancer Diagnostic Testing - Market report are Biopsy, Imaging, Others

1 Market Overview

1.1 Melanoma Skin Cancer Diagnostic Testing Product Introduction

1.2 Global Melanoma Skin Cancer Diagnostic Testing Market Size Forecast

1.3 Melanoma Skin Cancer Diagnostic Testing Market Trends & Drivers

1.3.1 Melanoma Skin Cancer Diagnostic Testing Industry Trends

1.3.2 Melanoma Skin Cancer Diagnostic Testing Market Drivers & Opportunity

1.3.3 Melanoma Skin Cancer Diagnostic Testing Market Challenges

1.3.4 Melanoma Skin Cancer Diagnostic Testing Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Melanoma Skin Cancer Diagnostic Testing Players Revenue Ranking (2023)

2.2 Global Melanoma Skin Cancer Diagnostic Testing Revenue by Company (2019-2024)

2.3 Key Companies Melanoma Skin Cancer Diagnostic Testing Manufacturing Base Distribution and Headquarters

2.4 Key Companies Melanoma Skin Cancer Diagnostic Testing Product Offered

2.5 Key Companies Time to Begin Mass Production of Melanoma Skin Cancer Diagnostic Testing

2.6 Melanoma Skin Cancer Diagnostic Testing Market Competitive Analysis

2.6.1 Melanoma Skin Cancer Diagnostic Testing Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Melanoma Skin Cancer Diagnostic Testing Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Melanoma Skin Cancer Diagnostic Testing as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Biopsy

3.1.2 Imaging

3.1.3 Others

3.2 Global Melanoma Skin Cancer Diagnostic Testing Sales Value by Type

3.2.1 Global Melanoma Skin Cancer Diagnostic Testing Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Melanoma Skin Cancer Diagnostic Testing Sales Value, by Type (2019-2030)

3.2.3 Global Melanoma Skin Cancer Diagnostic Testing Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hospitals

4.1.2 Dermatology Clinics

4.1.3 Diagnostic Laboratories

4.1.4 Others

4.2 Global Melanoma Skin Cancer Diagnostic Testing Sales Value by Application

4.2.1 Global Melanoma Skin Cancer Diagnostic Testing Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Melanoma Skin Cancer Diagnostic Testing Sales Value, by Application (2019-2030)

4.2.3 Global Melanoma Skin Cancer Diagnostic Testing Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Melanoma Skin Cancer Diagnostic Testing Sales Value by Region

5.1.1 Global Melanoma Skin Cancer Diagnostic Testing Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Melanoma Skin Cancer Diagnostic Testing Sales Value by Region (2019-2024)

5.1.3 Global Melanoma Skin Cancer Diagnostic Testing Sales Value by Region (2025-2030)

5.1.4 Global Melanoma Skin Cancer Diagnostic Testing Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Melanoma Skin Cancer Diagnostic Testing Sales Value, 2019-2030

5.2.2 North America Melanoma Skin Cancer Diagnostic Testing Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Melanoma Skin Cancer Diagnostic Testing Sales Value, 2019-2030

5.3.2 Europe Melanoma Skin Cancer Diagnostic Testing Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Melanoma Skin Cancer Diagnostic Testing Sales Value, 2019-2030

5.4.2 Asia Pacific Melanoma Skin Cancer Diagnostic Testing Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Melanoma Skin Cancer Diagnostic Testing Sales Value, 2019-2030

5.5.2 South America Melanoma Skin Cancer Diagnostic Testing Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Melanoma Skin Cancer Diagnostic Testing Sales Value, 2019-2030

5.6.2 Middle East & Africa Melanoma Skin Cancer Diagnostic Testing Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Melanoma Skin Cancer Diagnostic Testing Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Melanoma Skin Cancer Diagnostic Testing Sales Value

6.3 United States

6.3.1 United States Melanoma Skin Cancer Diagnostic Testing Sales Value, 2019-2030

6.3.2 United States Melanoma Skin Cancer Diagnostic Testing Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Melanoma Skin Cancer Diagnostic Testing Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Melanoma Skin Cancer Diagnostic Testing Sales Value, 2019-2030

6.4.2 Europe Melanoma Skin Cancer Diagnostic Testing Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Melanoma Skin Cancer Diagnostic Testing Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Melanoma Skin Cancer Diagnostic Testing Sales Value, 2019-2030

6.5.2 China Melanoma Skin Cancer Diagnostic Testing Sales Value by Type (%), 2023 VS 2030

6.5.3 China Melanoma Skin Cancer Diagnostic Testing Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Melanoma Skin Cancer Diagnostic Testing Sales Value, 2019-2030

6.6.2 Japan Melanoma Skin Cancer Diagnostic Testing Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Melanoma Skin Cancer Diagnostic Testing Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Melanoma Skin Cancer Diagnostic Testing Sales Value, 2019-2030

6.7.2 South Korea Melanoma Skin Cancer Diagnostic Testing Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Melanoma Skin Cancer Diagnostic Testing Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Melanoma Skin Cancer Diagnostic Testing Sales Value, 2019-2030

6.8.2 Southeast Asia Melanoma Skin Cancer Diagnostic Testing Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Melanoma Skin Cancer Diagnostic Testing Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Melanoma Skin Cancer Diagnostic Testing Sales Value, 2019-2030

6.9.2 India Melanoma Skin Cancer Diagnostic Testing Sales Value by Type (%), 2023 VS 2030

6.9.3 India Melanoma Skin Cancer Diagnostic Testing Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Myriad Genetics

7.1.1 Myriad Genetics Profile

7.1.2 Myriad Genetics Main Business

7.1.3 Myriad Genetics Melanoma Skin Cancer Diagnostic Testing Products, Services and Solutions

7.1.4 Myriad Genetics Melanoma Skin Cancer Diagnostic Testing Revenue (US$ Million) & (2019-2024)

7.1.5 Myriad Genetics Recent Developments

7.2 Abbott Laboratories

7.2.1 Abbott Laboratories Profile

7.2.2 Abbott Laboratories Main Business

7.2.3 Abbott Laboratories Melanoma Skin Cancer Diagnostic Testing Products, Services and Solutions

7.2.4 Abbott Laboratories Melanoma Skin Cancer Diagnostic Testing Revenue (US$ Million) & (2019-2024)

7.2.5 Abbott Laboratories Recent Developments

7.3 Foundation Medicine

7.3.1 Foundation Medicine Profile

7.3.2 Foundation Medicine Main Business

7.3.3 Foundation Medicine Melanoma Skin Cancer Diagnostic Testing Products, Services and Solutions

7.3.4 Foundation Medicine Melanoma Skin Cancer Diagnostic Testing Revenue (US$ Million) & (2019-2024)

7.3.5 Pathway Genomics Corporation Recent Developments

7.4 Pathway Genomics Corporation

7.4.1 Pathway Genomics Corporation Profile

7.4.2 Pathway Genomics Corporation Main Business

7.4.3 Pathway Genomics Corporation Melanoma Skin Cancer Diagnostic Testing Products, Services and Solutions

7.4.4 Pathway Genomics Corporation Melanoma Skin Cancer Diagnostic Testing Revenue (US$ Million) & (2019-2024)

7.4.5 Pathway Genomics Corporation Recent Developments

7.5 Cancer Genetics

7.5.1 Cancer Genetics Profile

7.5.2 Cancer Genetics Main Business

7.5.3 Cancer Genetics Melanoma Skin Cancer Diagnostic Testing Products, Services and Solutions

7.5.4 Cancer Genetics Melanoma Skin Cancer Diagnostic Testing Revenue (US$ Million) & (2019-2024)

7.5.5 Cancer Genetics Recent Developments

7.6 Castle Biosciences

7.6.1 Castle Biosciences Profile

7.6.2 Castle Biosciences Main Business

7.6.3 Castle Biosciences Melanoma Skin Cancer Diagnostic Testing Products, Services and Solutions

7.6.4 Castle Biosciences Melanoma Skin Cancer Diagnostic Testing Revenue (US$ Million) & (2019-2024)

7.6.5 Castle Biosciences Recent Developments

7.7 NeoGenomics

7.7.1 NeoGenomics Profile

7.7.2 NeoGenomics Main Business

7.7.3 NeoGenomics Melanoma Skin Cancer Diagnostic Testing Products, Services and Solutions

7.7.4 NeoGenomics Melanoma Skin Cancer Diagnostic Testing Revenue (US$ Million) & (2019-2024)

7.7.5 NeoGenomics Recent Developments

7.8 Dermtech

7.8.1 Dermtech Profile

7.8.2 Dermtech Main Business

7.8.3 Dermtech Melanoma Skin Cancer Diagnostic Testing Products, Services and Solutions

7.8.4 Dermtech Melanoma Skin Cancer Diagnostic Testing Revenue (US$ Million) & (2019-2024)

7.8.5 Dermtech Recent Developments

7.9 Sysmex Inostics

7.9.1 Sysmex Inostics Profile

7.9.2 Sysmex Inostics Main Business

7.9.3 Sysmex Inostics Melanoma Skin Cancer Diagnostic Testing Products, Services and Solutions

7.9.4 Sysmex Inostics Melanoma Skin Cancer Diagnostic Testing Revenue (US$ Million) & (2019-2024)

7.9.5 Sysmex Inostics Recent Developments

8 Industry Chain Analysis

8.1 Melanoma Skin Cancer Diagnostic Testing Industrial Chain

8.2 Melanoma Skin Cancer Diagnostic Testing Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Melanoma Skin Cancer Diagnostic Testing Sales Model

8.5.2 Sales Channel

8.5.3 Melanoma Skin Cancer Diagnostic Testing Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Myriad Genetics

Abbott Laboratories

Foundation Medicine

Pathway Genomics Corporation

List of Tables

Table 1. Melanoma Skin Cancer Diagnostic Testing Market Trends

Table 2. Melanoma Skin Cancer Diagnostic Testing Market Drivers & Opportunity

Table 3. Melanoma Skin Cancer Diagnostic Testing Market Challenges

Table 4. Melanoma Skin Cancer Diagnostic Testing Market Restraints

Table 5. Global Melanoma Skin Cancer Diagnostic Testing Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Melanoma Skin Cancer Diagnostic Testing Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Melanoma Skin Cancer Diagnostic Testing Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Melanoma Skin Cancer Diagnostic Testing Product Type

Table 9. Key Companies Time to Begin Mass Production of Melanoma Skin Cancer Diagnostic Testing

Table 10. Global Melanoma Skin Cancer Diagnostic Testing Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Melanoma Skin Cancer Diagnostic Testing as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Melanoma Skin Cancer Diagnostic Testing Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Melanoma Skin Cancer Diagnostic Testing Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Melanoma Skin Cancer Diagnostic Testing Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Melanoma Skin Cancer Diagnostic Testing Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Melanoma Skin Cancer Diagnostic Testing Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Melanoma Skin Cancer Diagnostic Testing Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Melanoma Skin Cancer Diagnostic Testing Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Melanoma Skin Cancer Diagnostic Testing Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Melanoma Skin Cancer Diagnostic Testing Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Melanoma Skin Cancer Diagnostic Testing Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Melanoma Skin Cancer Diagnostic Testing Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Melanoma Skin Cancer Diagnostic Testing Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Melanoma Skin Cancer Diagnostic Testing Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Melanoma Skin Cancer Diagnostic Testing Sales Value by Region (2019-2024) & (%)

Table 27. Global Melanoma Skin Cancer Diagnostic Testing Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Melanoma Skin Cancer Diagnostic Testing Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Melanoma Skin Cancer Diagnostic Testing Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Melanoma Skin Cancer Diagnostic Testing Sales Value, (2025-2030) & (US$ Million)

Table 31. Myriad Genetics Basic Information List

Table 32. Myriad Genetics Description and Business Overview

Table 33. Myriad Genetics Melanoma Skin Cancer Diagnostic Testing Products, Services and Solutions

Table 34. Revenue (US$ Million) in Melanoma Skin Cancer Diagnostic Testing Business of Myriad Genetics (2019-2024)

Table 35. Myriad Genetics Recent Developments

Table 36. Abbott Laboratories Basic Information List

Table 37. Abbott Laboratories Description and Business Overview

Table 38. Abbott Laboratories Melanoma Skin Cancer Diagnostic Testing Products, Services and Solutions

Table 39. Revenue (US$ Million) in Melanoma Skin Cancer Diagnostic Testing Business of Abbott Laboratories (2019-2024)

Table 40. Abbott Laboratories Recent Developments

Table 41. Foundation Medicine Basic Information List

Table 42. Foundation Medicine Description and Business Overview

Table 43. Foundation Medicine Melanoma Skin Cancer Diagnostic Testing Products, Services and Solutions

Table 44. Revenue (US$ Million) in Melanoma Skin Cancer Diagnostic Testing Business of Foundation Medicine (2019-2024)

Table 45. Foundation Medicine Recent Developments

Table 46. Pathway Genomics Corporation Basic Information List

Table 47. Pathway Genomics Corporation Description and Business Overview

Table 48. Pathway Genomics Corporation Melanoma Skin Cancer Diagnostic Testing Products, Services and Solutions

Table 49. Revenue (US$ Million) in Melanoma Skin Cancer Diagnostic Testing Business of Pathway Genomics Corporation (2019-2024)

Table 50. Pathway Genomics Corporation Recent Developments

Table 51. Cancer Genetics Basic Information List

Table 52. Cancer Genetics Description and Business Overview

Table 53. Cancer Genetics Melanoma Skin Cancer Diagnostic Testing Products, Services and Solutions

Table 54. Revenue (US$ Million) in Melanoma Skin Cancer Diagnostic Testing Business of Cancer Genetics (2019-2024)

Table 55. Cancer Genetics Recent Developments

Table 56. Castle Biosciences Basic Information List

Table 57. Castle Biosciences Description and Business Overview

Table 58. Castle Biosciences Melanoma Skin Cancer Diagnostic Testing Products, Services and Solutions

Table 59. Revenue (US$ Million) in Melanoma Skin Cancer Diagnostic Testing Business of Castle Biosciences (2019-2024)

Table 60. Castle Biosciences Recent Developments

Table 61. NeoGenomics Basic Information List

Table 62. NeoGenomics Description and Business Overview

Table 63. NeoGenomics Melanoma Skin Cancer Diagnostic Testing Products, Services and Solutions

Table 64. Revenue (US$ Million) in Melanoma Skin Cancer Diagnostic Testing Business of NeoGenomics (2019-2024)

Table 65. NeoGenomics Recent Developments

Table 66. Dermtech Basic Information List

Table 67. Dermtech Description and Business Overview

Table 68. Dermtech Melanoma Skin Cancer Diagnostic Testing Products, Services and Solutions

Table 69. Revenue (US$ Million) in Melanoma Skin Cancer Diagnostic Testing Business of Dermtech (2019-2024)

Table 70. Dermtech Recent Developments

Table 71. Sysmex Inostics Basic Information List

Table 72. Sysmex Inostics Description and Business Overview

Table 73. Sysmex Inostics Melanoma Skin Cancer Diagnostic Testing Products, Services and Solutions

Table 74. Revenue (US$ Million) in Melanoma Skin Cancer Diagnostic Testing Business of Sysmex Inostics (2019-2024)

Table 75. Sysmex Inostics Recent Developments

Table 76. Key Raw Materials Lists

Table 77. Raw Materials Key Suppliers Lists

Table 78. Melanoma Skin Cancer Diagnostic Testing Downstream Customers

Table 79. Melanoma Skin Cancer Diagnostic Testing Distributors List

Table 80. Research Programs/Design for This Report

Table 81. Key Data Information from Secondary Sources

Table 82. Key Data Information from Primary Sources

Table 83. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Melanoma Skin Cancer Diagnostic Testing Product Picture

Figure 2. Global Melanoma Skin Cancer Diagnostic Testing Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Melanoma Skin Cancer Diagnostic Testing Sales Value (2019-2030) & (US$ Million)

Figure 4. Melanoma Skin Cancer Diagnostic Testing Report Years Considered

Figure 5. Global Melanoma Skin Cancer Diagnostic Testing Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Melanoma Skin Cancer Diagnostic Testing Revenue in 2023

Figure 7. Melanoma Skin Cancer Diagnostic Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Biopsy Picture

Figure 9. Imaging Picture

Figure 10. Others Picture

Figure 11. Global Melanoma Skin Cancer Diagnostic Testing Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 12. Global Melanoma Skin Cancer Diagnostic Testing Sales Value Market Share by Type, 2023 & 2030

Figure 13. Product Picture of Hospitals

Figure 14. Product Picture of Dermatology Clinics

Figure 15. Product Picture of Diagnostic Laboratories

Figure 16. Product Picture of Others

Figure 17. Global Melanoma Skin Cancer Diagnostic Testing Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 18. Global Melanoma Skin Cancer Diagnostic Testing Sales Value Market Share by Application, 2023 & 2030

Figure 19. North America Melanoma Skin Cancer Diagnostic Testing Sales Value (2019-2030) & (US$ Million)

Figure 20. North America Melanoma Skin Cancer Diagnostic Testing Sales Value by Country (%), 2023 VS 2030

Figure 21. Europe Melanoma Skin Cancer Diagnostic Testing Sales Value (2019-2030) & (US$ Million)

Figure 22. Europe Melanoma Skin Cancer Diagnostic Testing Sales Value by Country (%), 2023 VS 2030

Figure 23. Asia Pacific Melanoma Skin Cancer Diagnostic Testing Sales Value (2019-2030) & (US$ Million)

Figure 24. Asia Pacific Melanoma Skin Cancer Diagnostic Testing Sales Value by Country (%), 2023 VS 2030

Figure 25. South America Melanoma Skin Cancer Diagnostic Testing Sales Value (2019-2030) & (US$ Million)

Figure 26. South America Melanoma Skin Cancer Diagnostic Testing Sales Value by Country (%), 2023 VS 2030

Figure 27. Middle East & Africa Melanoma Skin Cancer Diagnostic Testing Sales Value (2019-2030) & (US$ Million)

Figure 28. Middle East & Africa Melanoma Skin Cancer Diagnostic Testing Sales Value by Country (%), 2023 VS 2030

Figure 29. Key Countries/Regions Melanoma Skin Cancer Diagnostic Testing Sales Value (%), (2019-2030)

Figure 30. United States Melanoma Skin Cancer Diagnostic Testing Sales Value, (2019-2030) & (US$ Million)

Figure 31. United States Melanoma Skin Cancer Diagnostic Testing Sales Value by Type (%), 2023 VS 2030

Figure 32. United States Melanoma Skin Cancer Diagnostic Testing Sales Value by Application (%), 2023 VS 2030

Figure 33. Europe Melanoma Skin Cancer Diagnostic Testing Sales Value, (2019-2030) & (US$ Million)

Figure 34. Europe Melanoma Skin Cancer Diagnostic Testing Sales Value by Type (%), 2023 VS 2030

Figure 35. Europe Melanoma Skin Cancer Diagnostic Testing Sales Value by Application (%), 2023 VS 2030

Figure 36. China Melanoma Skin Cancer Diagnostic Testing Sales Value, (2019-2030) & (US$ Million)

Figure 37. China Melanoma Skin Cancer Diagnostic Testing Sales Value by Type (%), 2023 VS 2030

Figure 38. China Melanoma Skin Cancer Diagnostic Testing Sales Value by Application (%), 2023 VS 2030

Figure 39. Japan Melanoma Skin Cancer Diagnostic Testing Sales Value, (2019-2030) & (US$ Million)

Figure 40. Japan Melanoma Skin Cancer Diagnostic Testing Sales Value by Type (%), 2023 VS 2030

Figure 41. Japan Melanoma Skin Cancer Diagnostic Testing Sales Value by Application (%), 2023 VS 2030

Figure 42. South Korea Melanoma Skin Cancer Diagnostic Testing Sales Value, (2019-2030) & (US$ Million)

Figure 43. South Korea Melanoma Skin Cancer Diagnostic Testing Sales Value by Type (%), 2023 VS 2030

Figure 44. South Korea Melanoma Skin Cancer Diagnostic Testing Sales Value by Application (%), 2023 VS 2030

Figure 45. Southeast Asia Melanoma Skin Cancer Diagnostic Testing Sales Value, (2019-2030) & (US$ Million)

Figure 46. Southeast Asia Melanoma Skin Cancer Diagnostic Testing Sales Value by Type (%), 2023 VS 2030

Figure 47. Southeast Asia Melanoma Skin Cancer Diagnostic Testing Sales Value by Application (%), 2023 VS 2030

Figure 48. India Melanoma Skin Cancer Diagnostic Testing Sales Value, (2019-2030) & (US$ Million)

Figure 49. India Melanoma Skin Cancer Diagnostic Testing Sales Value by Type (%), 2023 VS 2030

Figure 50. India Melanoma Skin Cancer Diagnostic Testing Sales Value by Application (%), 2023 VS 2030

Figure 51. Melanoma Skin Cancer Diagnostic Testing Industrial Chain

Figure 52. Melanoma Skin Cancer Diagnostic Testing Manufacturing Cost Structure

Figure 53. Channels of Distribution (Direct Sales, and Distribution)

Figure 54. Bottom-up and Top-down Approaches for This Report

Figure 55. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions